STEM CELL THERAPEUTICS RELEASES DATA FROM STROKE STUDY

Stem Cell Therapeutics has announced the results from a controlled study testing NTx-265 therapy in a rodent model of stroke. The data confirms that, in test animals, treatment with the NTx-265 regimen of drugs produces substantial and significant recovery of lost neurological function. The drug is a peripherally administered proprietary dose and schedule of human chorionic gonadotropin followed by erythropoietin, which have both been marketed for years in other medical applications.

Researchers are also currently enrolling stroke patients in a Phase IIa clinical trial investigating the safety of NTx-265.

Stroke is the third leading cause of death in the United States, where it affects 700,000 people each year, and is the second leading cause of death worldwide. It is also the leading cause of long-term disability.